Biocore Co Ltd (216400)

Invites Biocore Co., Ltd. provides bioanalytical and central lab services in South Korea and internationally. It offers bioanalytical testing service during biological equivalence tests, clinical trials, toxicokinetics, nonclinical trials, vivo dynamic analysis, comparative dissolution test, and biomarker analysis; provides project strategic planning, medical translation, clinical research, quality assurance, monitoring, and data management for clinical services; and offers services, such as pharmaceutical quality control testing, emergency testing for food and drug safety, impurity testing, testing for licensed pharmaceutical products, and pharmaceutical stability testing. The company also provides disease susceptibility and anticancer drug susceptibility test; personalized genetic testing services, chromosomal microarray analysis, newborn screening, diagnostic exome sequencing, and non-invasive prenatal testing; and sequencing, microarray analysis, Real-Time PCR analysis services. In addition, it offers Real Time PCR Kits; ApoE genotype analysis products; and HLA-B*27 and HLA-B*51 genetic analysis products. Further, the company provides cold-chain and sample transport packaging, data logger device, as well as logistics services. The company was formerly known as Biocore Co., Ltd. and changed its name to Invites Biocore Co., Ltd. in March 2021. Invites Biocore Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.